Gilead Partners With Vir Biotechnology in Cancer Therapy Deal Worth Up to $1.87 Billion
Gilead Sciences, Inc. (GILD) has entered into a license and collaboration agreement with Vir Biotechnology, Inc. (VIR) to discover and engineer three T-cell engager candidates targeting solid tumors. Under the agreement, Vir will receive $90 million upfront and up to $45 million in near-term preclinical milestones. Vir is also eligible for up to $1.74 billion in additional development, regulatory, and commercial milestone payments, along with sales royalties, while Gilead gains exclusive global rights to commercialize the candidates.
The collaboration supports efforts by Gilead Sciences, Inc. (GILD) to expand its oncology portfolio and diversify revenue away from its primary HIV treatment business. While existing oncology drugs such as Trodelvy have helped diversify sales, Gilead faces competition in cell therapy from rivals like Bristol Myers Squibb Company (BMY), as well as competing therapies from AstraZeneca PLC (AZN) and Daiichi Sankyo.
Investors will monitor Gilead's progress in advancing these preclinical candidates alongside its existing oncology assets. Key upcoming catalysts include a December 23 regulatory decision for anito-cel, a multiple myeloma therapy acquired through Arcellx. Market participants will also track how deal costs and upfront payments affect Gilead's near-term profitability.
Key points
- Gilead Sciences, Inc. (GILD) agreed to collaborate with Vir Biotechnology, Inc. (VIR) on three T-cell engager candidates for solid tumors.
- Vir will receive $90 million upfront and up to $45 million in near-term preclinical milestones, with potential future milestones totaling $1.74 billion plus royalties.
- Gilead receives exclusive rights to develop and commercialize the resulting cancer candidate therapies globally.
- The deal supports Gilead's strategy to broaden its oncology pipeline beyond its primary HIV revenue base.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What are the details of Gilead's agreement with Vir Biotechnology?
Gilead Sciences, Inc. (GILD) is paying Vir Biotechnology, Inc. (VIR) $90 million upfront and up to $45 million in near-term preclinical milestones to co-develop three solid tumor therapies, with up to $1.74 billion in prospective future milestones and royalties.
Why is Gilead Sciences expanding its oncology pipeline?
Gilead Sciences, Inc. (GILD) is working to broaden its product line and diversify revenue beyond its main HIV treatment business into higher-growth oncology and immunology markets.
What upcoming regulatory milestones does Gilead have in oncology?
Gilead has a December 23 regulatory action date for anito-cel, a treatment candidate for relapsed or refractory multiple myeloma acquired through its Arcellx transaction.